Changes in Hong Kong stocks | Tongyuankang Pharmaceutical-B (02410) reached a strategic cooperation with Qilu Pharmaceutical to accelerate commercialization of TY-9591

The Zhitong Finance App learned that Tongyuankang Pharmaceutical-B (02410) was nearly 15% higher. As of press release, it had risen 14.96% to HK$9.68, with a turnover of HK$3.238 million.

According to the news, on July 21, Tongyuankang Pharmaceutical and Qilu Pharmaceutical or their designated related parties reached a licensing and cooperation agreement and supply and commercialization agreement, and will work together to develop, produce, and commercialize TY-9591 APIs in mainland China. At the same time, Qilu Pharmaceutical will also make an equity investment in Tongyuankang Pharmaceutical, and the two sides will establish a deep strategic partnership. Through this cooperation, Tongyuankang Pharmaceutical will have the right to collect RMB 700 million in share subscription payments and cash down payments, as well as registration milestone payments of up to RMB 2.06 billion for regulatory approval and indication extensions of TY-9591.

It is worth noting that TY-9591's new drug marketing application (NDA) was officially accepted by the China National Drug Administration Drug Evaluation Center (CDE) in early 2026 and included in the priority review and approval process. It is currently in the NDA review stage. After approval for marketing, TY-9591 is expected to provide better treatment options for patients with EGFR mutation NSCLC to further meet unmet clinical needs.